Cargando…
CD206 Expression in Induced Microglia-Like Cells From Peripheral Blood as a Surrogate Biomarker for the Specific Immune Microenvironment of Neurosurgical Diseases Including Glioma
Targeting the unique glioma immune microenvironment is a promising approach in developing breakthrough immunotherapy treatments. However, recent advances in immunotherapy, including the development of immune checkpoint inhibitors, have not improved the outcomes of patients with glioma. A way of moni...
Autores principales: | Tanaka, Shunya, Ohgidani, Masahiro, Hata, Nobuhiro, Inamine, Shogo, Sagata, Noriaki, Shirouzu, Noritoshi, Mukae, Nobutaka, Suzuki, Satoshi O., Hamasaki, Hideomi, Hatae, Ryusuke, Sangatsuda, Yuhei, Fujioka, Yutaka, Takigawa, Kosuke, Funakoshi, Yusuke, Iwaki, Toru, Hosoi, Masako, Iihara, Koji, Mizoguchi, Masahiro, Kato, Takahiro A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276757/ https://www.ncbi.nlm.nih.gov/pubmed/34267749 http://dx.doi.org/10.3389/fimmu.2021.670131 |
Ejemplares similares
-
IM-03 CD206 expression in peripheral blood-derived induced-microglia-like cells as a surrogate biomarker for the specific immune microenvironment of glioma
por: Hata, Nobuhiro, et al.
Publicado: (2020) -
Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma)
por: Funakoshi, Yusuke, et al.
Publicado: (2021) -
ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application
por: Funakoshi, Yusuke, et al.
Publicado: (2020) -
Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2020) -
Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment
por: Funakoshi, Yusuke, et al.
Publicado: (2021)